Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Abstract: The present application provides a load balancing system. In an example, the load balancing system includes a client, a first load balancer coupled to the client, a plurality of security forwarding devices whose load sides are coupled to the first load balancer and forwarding sides are coupled to a second load balancer, the second load balancer, and a server coupled with the second load balancer. In the load balancing system, service traffic resources can be accurately allocated to the target security forwarding device selected by the scheduling algorithm, so as to balance load.

Abstract: A method and device for displaying reference content, and a storage medium thereof are provided. In some embodiments, the method includes displaying a first interface in response to an operation of enabling the first interface; displaying multiple second interfaces on the first interface in a form of floating window in response to an operation of enabling reference content, the multiple second interfaces including different reference content respectively; and displaying, in response to an operation of selecting a second interface from the multiple second interfaces, the selected second interface on the first interface in an overlaying manner. The formation arranging efficiency and communication efficiency between game players and the reference content can be improved by the above technical solution.

Abstract: The disclosure relates to a method and device for displaying a floating window. The method includes monitoring an amount of floating windows that are created on a desktop for respective ones of a plurality of applications; determining that there is more than one of the plurality of applications for which a floating window is created on the desktop; forbidding permissions of multiple floating windows based on the determination; launching a system floating window; hiding and containing the multiple floating windows in the system floating window; receiving an activating instruction for the system floating window; extending and displaying the multiple floating windows contained in the system floating window; receiving a selection instruction for the multiple floating windows; displaying a selected floating window of the multiple floating windows; allowing a permission of the selected floating window; and masking a permission of the system floating window.

Abstract: A method for displaying an application interface on a terminal. The method includes determining a first application of an application group. The application group includes multiple identical applications installed on the terminal, and the first application is a most recently used application of the multiple identical applications. The method further includes displaying application indication information in a specific area in an interface of the terminal, for indicating the first application.

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: An airbag inflator is provided, including an inflator module, an exhaust hood, a filter element, exhaust holes, and a flow-guiding loop. The exhaust hood corresponds to one end of the inflator module to form an accommodating space in a concave shape, and the exhaust hood is set on the inflator module by the accommodating space. The filter element is disposed on the sidewall of the exhaust hood and covers the exhaust holes. The exhaust holes are disposed on the sidewall of the exhaust hood and are adjacent to the exhaust hood opposite to one end of the inflator module. One side of the flow-guiding loop is attached to the exhaust hood corresponding to one side of the inflator module, and the other side of the flow-guiding loop extending to the inflator module to form an annular convex rib.

Abstract: A method for displaying an application interface on a terminal. The method includes determining a first application of an application group. The application group includes multiple identical applications installed on the terminal, and the first application is a most recently used application of the multiple identical applications. The method further includes displaying application indication information in a specific area in an interface of the terminal, for indicating the first application.

Abstract: A method performed by a communications system, for authenticating a station, STA, to access a network is provided. The STA is capable of communicating with a light source. The method includes sending, by a management server to a controller of the light source, network access information, sending, by the light source to the STA, the received network access information, which network access information is sent to the STA via a Visual Light Communication (VLC) channel. The VLC channel is emitted from the light source and received by a light detector in the STA. The STA is authenticated to the network by sending the received network access information to an Access Point (AP) operating in the network in which the STA communicates with the AP via a communication channel.

Abstract: Provided are compounds of formula (I), wherein R1, Y, X1, X2, R2, R3, R4, R5, R6 and m have any of the values defined in the specification and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: Provided herein are compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: An application triggering method and device are provided in the field of terminals. The terminal device sets at least two different triggering passwords for at least two instances of an application corresponding to an application icon on a user interface on the display. The terminal device acquires an input password after a triggering operation over the application icon is detected on the user interface. The terminal device triggers a target instance of the application according to the input password, where the target instance refers to an instance for which one of the at least two different triggering passwords is the same as the input password.

Abstract: An inductor is disclosed, including a first wire, a non-conductive material, and a shell. The non-conductive material may cover the first wire, with a portion of each end of the first wire uncovered. The shell may include a top portion and a bottom portion and include at least one magnetized layer and at least one gap between the first portion and the second portion. The shell may also surround a portion of the non-conductive material.

Abstract: The present invention relates to the well drilling field in petrochemical industry, in particular to use of dual-cation fluorocarbon surfactant as amphiphobic wettability reversal agent in drilling fluid. The dual-cation fluorocarbon surfactant is a dual-cation fluorocarbon surfactant of which the cation part is represented by the following formula (1). The dual-cation fluorocarbon surfactant of the present invention can serve as wettability reversal agent when it is used for oil-gas drilling to enable rock amphiphobic, and is an amphiphobic wettability reversal agent which can cause rock surface to be non-hydrophilic and non-lipophilic. Using of dual-cation fluorocarbon surfactant, especially when drilling highly hydrous mud shale, can avoid permeation of water and oil into the rock effectively and thereby a capillary phenomenon can be prevented, and an effect of stabilizing the well wall and protecting the reservoir is attained.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Abstract: The present invention provides for compounds of formula (I) wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).